KainosMed Receives Approval for Phase 2 Trial Plan of Parkinson's Disease Treatment 'KM-819'

[Asia Economy Reporter Minwoo Lee] Kainosmed announced on the 22nd that it has received approval from the Ministry of Food and Drug Safety for the phase 2 clinical trial plan of KM-819, a treatment for multiple system atrophy (MSA). Multiple system atrophy is a type of disease classified under Parkinsonian syndromes.

The company stated, "The investigational drug KM-819 is expected to protect dopamine-producing neurons from cell death by inhibiting the overexpression of FAF1, which induces cell apoptosis, thereby slowing the pathological progression of multiple system atrophy through a novel pharmacological mechanism." They added, "In this clinical trial, it is expected that the KM-819 treatment group will show a clinically significant slower progression of multiple system atrophy and improved neurological assessment results compared to the control group."